Health Industry News
Elite PR joins Global Health Marketing & Communications (GHMC) as exclusive Taiwanese agency
Taiwan-based communications agency, Elite PR, has this week joined the world’s largest, and most robust network of independent healthcare agencies – Global Health Marketing & Communications (GHMC). Bolstering GHMC’s capabilities and footprint in the Asia Pacific (APAC) region, Elite PR has an exemplary, 35+ year-strong record of experience in the Taiwanese health sector. Established in…
Read MoreVIVA! Communications welcomes new recruits
Today we have welcomed two new members to VIVA! Communications – PR Consultant Sophie Harrison and Account Executive, Sophie Ridley. Both Sophies will be charged with supporting the servicing of our VIVA! clientele, and further strengthening our agency’s health communications, digital and social expertise. Sophie H specialises in Sports Science and Public Health. She has…
Read MoreGlobal Health Marketing and Communications (GHMC) welcomes Improve Comunicaciones as an exclusive agency partner in Mexico, strengthening network’s capabilities in Latin America
As the exclusive Australian partner of Global Health Marketing and Communications (GHMC) – the largest and most robust network of independent healthcare agencies worldwide – VIVA! Communications extends a warm welcome to our newest member – Improve Comunicaciones. The addition of the Mexican-based, strategic consulting agency to GHMC, strengthens our GHMC network’s offering, and capabilities…
Read MoreNew Colombian comms partner strengthening our Global Health Marketing & Communications capabilities
To further strengthen our global network’s health communications expertise, Global Health Marketing & Communications (GHMC) today announced the addition of its newest member, Monodual Libera Ideas, a Colombian-based strategic communications, and consulting firm. GHMC is the world’s largest and most robust network of independent healthcare agencies, for which we – VIVA! Communications – have represented…
Read MoreTick of approval needed for Alzheimer’s disease medication in AUS
There are calls for the Therapeutic Goods Administration (TGA) to greenlight a breakthrough medication with the potential to slow the progression of Alzheimer’s disease. The Federal Drug Administration (FDA) recently approved humanised monoclonal antibody Lecanemab for use in patients with the neurodegenerative disease, in the wake of promising clinical trial outcomes. The medication, marketed as…
Read More